4.6 Article

A Deep Learning Approach for Automated Diagnosis and Multi-Class Classification of Alzheimer's Disease Stages Using Resting-State fMRI and Residual Neural Networks

Journal

JOURNAL OF MEDICAL SYSTEMS
Volume 44, Issue 2, Pages -

Publisher

SPRINGER
DOI: 10.1007/s10916-019-1475-2

Keywords

Alzheimer's disease; Functional magnetic resonance imaging (fMRI); Diagnosis; Multi-class; Classification; Deep learning; Residual neural networks

Funding

  1. HEC Pakistan [NRPU-4223]
  2. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  3. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  4. National Institute on Aging
  5. AbbVie
  6. Alzheimer's Association
  7. Alzheimer's Drug Discovery Foundation
  8. Araclon Biotech
  9. BioClinica, Inc.
  10. Biogen
  11. Bristol-Myers Squibb Company
  12. CereSpir, Inc.
  13. Cogstate
  14. Eisai Inc.
  15. Elan Pharmaceuticals, Inc.
  16. Eli Lilly and Company
  17. EuroImmun
  18. Fujirebio
  19. GE Healthcare
  20. IXICO Ltd.
  21. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  22. Johnson & Johnson Pharmaceutical Research & Development LLC.
  23. Lumosity
  24. Lundbeck
  25. Merck Co., Inc.
  26. Meso Scale Diagnostics, LLC.
  27. NeuroRx Research
  28. Neurotrack Technologies
  29. Novartis Pharmaceuticals Corporation
  30. Pfizer Inc.
  31. Piramal Imaging
  32. Servier
  33. Takeda Pharmaceutical Company
  34. Transition Therapeutics
  35. Canadian Institutes of Health Research
  36. Artificial Intelligence and Data Analytics (AIDA) Lab Prince Sultan University Riyadh Saudi Arabia
  37. F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.
  38. National Institute of Biomedical Imaging and Bioengineering

Ask authors/readers for more resources

Alzheimer's disease (AD) is an incurable neurodegenerative disorder accounting for 70%-80% dementia cases worldwide. Although, research on AD has increased in recent years, however, the complexity associated with brain structure and functions makes the early diagnosis of this disease a challenging task. Resting-state functional magnetic resonance imaging (rs-fMRI) is a neuroimaging technology that has been widely used to study the pathogenesis of neurodegenerative diseases. In literature, the computer-aided diagnosis of AD is limited to binary classification or diagnosis of AD and MCI stages. However, its applicability to diagnose multiple progressive stages of AD is relatively under-studied. This study explores the effectiveness of rs-fMRI for multi-class classification of AD and its associated stages including CN, SMC, EMCI, MCI, LMCI, and AD. A longitudinal cohort of resting-state fMRI of 138 subjects (25 CN, 25 SMC, 25 EMCI, 25 LMCI, 13 MCI, and 25 AD) from Alzheimer's Disease Neuroimaging Initiative (ADNI) is studied. To provide a better insight into deep learning approaches and their applications to AD classification, we investigate ResNet-18 architecture in detail. We consider the training of the network from scratch by using single-channel input as well as performed transfer learning with and without fine-tuning using an extended network architecture. We experimented with residual neural networks to perform AD classification task and compared it with former research in this domain. The performance of the models is evaluated using precision, recall, f1-measure, AUC and ROC curves. We found that our networks were able to significantly classify the subjects. We achieved improved results with our fine-tuned model for all the AD stages with an accuracy of 100%, 96.85%, 97.38%, 97.43%, 97.40% and 98.01% for CN, SMC, EMCI, LMCI, MCI, and AD respectively. However, in terms of overall performance, we achieved state-of-the-art results with an average accuracy of 97.92% and 97.88% for off-the-shelf and fine-tuned models respectively. The Analysis of results indicate that classification and prediction of neurodegenerative brain disorders such as AD using functional magnetic resonance imaging and advanced deep learning methods is promising for clinical decision making and have the potential to assist in early diagnosis of AD and its associated stages.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available